Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OMNICELL, INC. Director's Dealing 2016

Feb 8, 2016

31980_dirs_2016-02-08_f0f74e51-3c15-4b9c-861e-4a0f1f330bca.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OMNICELL, Inc (OMCL)
CIK: 0000926326
Period of Report: 2016-02-04

Reporting Person: Kuipers Peter J. (Executive V.P. CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-02-04 Common Stock A 2170 Acquired 23634 Direct
2016-02-04 Common Stock A 7220 Acquired 30854 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-02-04 Stock Option (Right to Buy) $27.70 A 17420 Acquired 2026-02-04 Common Stock (17420) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 21464 Direct

Footnotes

F1: Shares shall vest ratably over 48 month period, with a year cliff.

F2: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years.

F3: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2017 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2017 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance.